These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 21170646)

  • 1. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
    Di Giacomo AM; Danielli R; Calabrò L; Bertocci E; Nannicini C; Giannarelli D; Balestrazzi A; Vigni F; Riversi V; Miracco C; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2011 Apr; 60(4):467-77. PubMed ID: 21170646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
    Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
    Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
    Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
    PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
    Alexander M; Mellor JD; McArthur G; Kee D
    Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.
    Maio M; Danielli R; Chiarion-Sileni V; Pigozzo J; Parmiani G; Ridolfi R; De Rosa F; Del Vecchio M; Di Guardo L; Queirolo P; Picasso V; Marchetti P; De Galitiis F; Mandalà M; Guida M; Simeone E; Ascierto PA
    Ann Oncol; 2013 Nov; 24(11):2911-5. PubMed ID: 24067719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.
    Simeone E; Gentilcore G; Giannarelli D; Grimaldi AM; Caracò C; Curvietto M; Esposito A; Paone M; Palla M; Cavalcanti E; Sandomenico F; Petrillo A; Botti G; Fulciniti F; Palmieri G; Queirolo P; Marchetti P; Ferraresi V; Rinaldi G; Pistillo MP; Ciliberto G; Mozzillo N; Ascierto PA
    Cancer Immunol Immunother; 2014 Jul; 63(7):675-83. PubMed ID: 24695951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme.
    Chiarion Sileni V; Pigozzo J; Ascierto PA; Grimaldi AM; Maio M; Di Guardo L; Marchetti P; de Rosa F; Nuzzo C; Testori A; Cocorocchio E; Bernengo MG; Guida M; Marconcini R; Merelli B; Parmiani G; Rinaldi G; Aglietta M; Grosso M; Queirolo P
    J Exp Clin Cancer Res; 2014 Apr; 33(1):30. PubMed ID: 24708900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
    Danielli R; Ridolfi R; Chiarion-Sileni V; Queirolo P; Testori A; Plummer R; Boitano M; Calabrò L; Rossi CD; Giacomo AM; Ferrucci PF; Ridolfi L; Altomonte M; Miracco C; Balestrazzi A; Maio M
    Cancer Immunol Immunother; 2012 Jan; 61(1):41-8. PubMed ID: 21833591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.
    Altomonte M; Di Giacomo A; Queirolo P; Ascierto P; Spagnolo F; Bajetta E; Calabrò L; Danielli R; de Rosa F; Maur M; Chiarion-Sileni V; Ferrucci P; Giannarelli D; Testori A; Ridolfi R; Maio M
    J Exp Clin Cancer Res; 2013 Oct; 32(1):82. PubMed ID: 24423086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
    Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
    J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
    Del Vecchio M; Di Guardo L; Ascierto PA; Grimaldi AM; Sileni VC; Pigozzo J; Ferraresi V; Nuzzo C; Rinaldi G; Testori A; Ferrucci PF; Marchetti P; De Galitiis F; Queirolo P; Tornari E; Marconcini R; Calabrò L; Maio M
    Eur J Cancer; 2014 Jan; 50(1):121-7. PubMed ID: 24100024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.
    Ascierto PA; Simeone E; Sileni VC; Pigozzo J; Maio M; Altomonte M; Del Vecchio M; Di Guardo L; Marchetti P; Ridolfi R; Cognetti F; Testori A; Bernengo MG; Guida M; Marconcini R; Mandalà M; Cimminiello C; Rinaldi G; Aglietta M; Queirolo P
    J Transl Med; 2014 May; 12():116. PubMed ID: 24885479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases.
    Queirolo P; Spagnolo F; Ascierto PA; Simeone E; Marchetti P; Scoppola A; Del Vecchio M; Di Guardo L; Maio M; Di Giacomo AM; Antonuzzo A; Cognetti F; Ferraresi V; Ridolfi L; Guidoboni M; Guida M; Pigozzo J; Chiarion Sileni V
    J Neurooncol; 2014 May; 118(1):109-16. PubMed ID: 24532241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
    Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B
    J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
    Ku GY; Yuan J; Page DB; Schroeder SE; Panageas KS; Carvajal RD; Chapman PB; Schwartz GK; Allison JP; Wolchok JD
    Cancer; 2010 Apr; 116(7):1767-75. PubMed ID: 20143434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.
    Di Giacomo AM; Calabrò L; Danielli R; Fonsatti E; Bertocci E; Pesce I; Fazio C; Cutaia O; Giannarelli D; Miracco C; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2013 Jun; 62(6):1021-8. PubMed ID: 23591982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.
    Wilgenhof S; Du Four S; Everaert H; Neyns B
    Cancer Invest; 2012 Dec; 30(10):712-20. PubMed ID: 23043499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
    Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
    Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
    J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma.
    Geoerger B; Bergeron C; Gore L; Sender L; Dunkel IJ; Herzog C; Brochez L; Cruz O; Nysom K; Berghorn E; Simsek B; Shen J; Pappo A
    Eur J Cancer; 2017 Nov; 86():358-363. PubMed ID: 29100190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.